Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Inflammatory Bowel Disease II: Crohn's Disease

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient and physician outcomes of a store-and-forward teledermatology application in Germany.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same author

Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same author

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same author

Higher levels of response on clinical atopic dermatitis severity measures are associated with meaningful improvements in patient-reported symptom and quality of life measures: Integrated analysis of three Upadacitinib phase 3 trials.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same author

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same author

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2026

Measuring Psoriasis Severity at Home

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

[Psoriasis arthritis. An interdisciplinary challenge].

M A Radtke¹, K Reich, F Beikert

¹Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, Competenzzentrum Versorgungsforschung in der Dermatologie, Universitätsklinikum Hamburg-Eppendorf. m.radtke@uke.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete

|October 1, 2011

Summary

This summary is machine-generated.

Psoriatic arthritis (PsA) is a spondylarthropathy that benefits from multidisciplinary care. Advances in understanding and treatment improve patient outcomes and quality of life.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Measuring Psoriasis Severity at Home

Measuring Psoriasis Severity at Home

Published on: March 1, 2024

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

Area of Science:

Rheumatology and Dermatology
Immunology
Genetics

Context:

Psoriatic arthritis (PsA) is a complex spondylarthropathy.
Clinical and serological features guide classification.
Association with psoriasis and nail psoriasis is key.

Purpose:

To highlight advancements in understanding PsA pathophysiology and genetics.
To emphasize the role of multidisciplinary collaboration in PsA management.
To review the impact of novel therapeutic strategies.

Summary:

PsA classification is based on clinical, serological, and immunological characteristics.
Pathophysiological and genetic insights have driven new treatment development.
Multidisciplinary efforts enhance early diagnosis and treatment efficacy.

Impact:

New treatments significantly reduce radiologic progression.
Clinical symptoms are ameliorated, improving function.
Quality of life is enhanced for PsA patients.